Seamless transition! Keyuan Pharmaceutical appoints new leadership team, is the growth logic unchanged?

Ask AI · How will the new management team’s background help Kelon Pharmaceutical respond to industry challenges?

Produced | China-Visit Network

Reviewed by | Li Xiaoyan

On March 13, Kelon Pharmaceutical (301281.SZ) released an announcement. The company’s President Gao Chunpo resigned from his positions as President and legal representative due to “work adjustments.” After leaving, he would no longer hold any position at the company. On the same day, the company quickly completed the appointment of its new management team: Wei Zhiguo was hired as the new President, and Li Yanbing was appointed Vice President and Chief Financial Officer, with both terms running until the expiration of the term of the fourth session of the board of directors. This smooth handover—resigning and arriving in the same stroke—signals that this growth-oriented pharmaceutical company has officially entered a new cycle of business management, anchoring a new course aimed at improving quality and efficiency and breaking through to drive growth amid industry change.

The announcement’s neutral wording of “work adjustments,” together with the arrangement that “after leaving, he will no longer hold any position,” conveys the rationality and efficiency of Kelon Pharmaceutical’s management reshuffle. During Gao Chunpo’s tenure, he led the company in achieving phased results in areas including product planning, market expansion, and governance standardization, laying a solid foundation for the company’s subsequent development. In the announcement, the company expressed its thanks for his diligent performance of duties and contributions, reflecting respect for and inheritance of prior accumulated efforts.

The key highlight of this transition lies in seamless continuity. The newly appointed management team all hold key core posts: Wei Zhiguo provides overall command of operations and management, while Li Yanbing takes charge of finance and internal control. Their responsibilities are clear and their strengths are complementary, allowing them to quickly form a new operating synergy. This arrangement not only ensures continuity in the company’s operations, but also provides dual support for strategic implementation and risk management—an important reflection of the maturity of corporate governance at a listed company.

Wei Zhiguo, the newly appointed President, was born in 1979. He holds a bachelor’s degree and an EMBA master’s degree, and he has qualifications as a registered safety engineer. His work history covers management positions across the entire pharmaceutical industry chain. He previously served as President of Shanghai Huatong Pharmaceutical, Assistant to the Chairman of the Board of Beijing Beilu Pharmaceutical, and Head of the Operations and Management Department at Sichuan Huiyu Pharmaceutical. Before joining Kelon Pharmaceutical, he served as President of Shandong Linuo Pharmaceutical.

Judging from his background, Wei Zhiguo is a typical operations and management executive, with both strategic vision and execution capability. Through his experience in multiple pharmaceutical companies, he is familiar with the full process of production operations, team management, and market expansion. He is also adept at optimizing management and boosting performance during industry cycles. His “external appointment” rather than internal promotion background also brings Kelon Pharmaceutical external industry resources and advanced management experience, which is expected to inject new growth momentum into the company.

Li Yanbing, who took office at the same time as Wei Zhiguo, was born in 1982. She holds a master’s degree in accounting from Renmin University of China and holds the CMA (Certified Management Accountant, United States) qualification. She previously served as Financial Controller of Yiling Wanzhou International Pharmaceutical.

As she has long focused on financial management in the pharmaceutical industry, she has strong capabilities in financial planning, cost control, and risk avoidance.

A promotion of the finance lead to the level of Vice President is a typical signal for pharmaceutical companies to strengthen financial control and improve operating quality. Li Yanbing’s joining will help Kelon Pharmaceutical build a more rigorous internal control system and a more efficient capital operation mechanism. At the same time, it will provide data support and a financial perspective for operational decision-making, helping the company hold the line on profitability and optimize asset quality against the backdrop of centralized procurement becoming the norm and intensifying industry competition.

Kelon Pharmaceutical is currently in a growth stage. Although there is still a gap in scale compared with industry leaders, the fundamentals are solid, providing room for the new management team to fully apply its capabilities. In the first three quarters of 2025, the company achieved operating revenue of 303 million yuan, attributable net profit of 31.47 million yuan, with an overall profit margin of about 10%. It is at a reasonable level in the field of specialty chemical drugs and active pharmaceutical ingredients. As of the end of the third quarter, total assets were 1.606 billion yuan, shareholders’ equity was 1.371 billion yuan, and cash flow conditions were healthy. Net cash flow from operating activities was 27.2399 million yuan, up 14.11% year over year—its “blood-making capability” is solid.

In the short term, the company faces industry-wide challenges: in 2025, attributable net profit is expected to decline 70%–80% year over year, mainly due to factors including expansion of the dosage form market and litigation-related expenses from subsidiaries. However, this is not a decline in core competitiveness, but a phase of pain during an industry adjustment period. The company is proactively responding. In the first three quarters, R&D expenses increased 58.75% year over year to 35.49 million yuan, strengthening innovation investment and market layout to accumulate momentum for long-term development.

Amid industry transformation, the new management team composed of Wei Zhiguo and Li Yanbing needs to make precise efforts to stabilize the core business and pursue new growth. Key issues are concentrated in three areas:

First, optimize the product mix to strengthen core competitiveness. Kelon Pharmaceutical needs to focus on its advantageous products, increase R&D investment and evidence-based medical research, and improve product quality and brand strength. At the same time, it should optimize capacity planning and implement a strategy of “opening the market in the off-season and supplying the market in the peak season.” Through large-scale production to reduce costs and increase efficiency, the company can withstand pressure from competition in existing market supply.

Second, strengthen financial control to improve operating quality. Relying on Li Yanbing’s professional capabilities, the company will further sort out accounts receivable, control inventory risk, and establish a refined capital management system. By enabling finance to optimize business processes and improve expense efficiency, it will achieve a dual-wheel drive of “increasing revenue and reducing costs,” holding the line on profitability amid industry fluctuations.

Third, expand the boundaries of growth and activate growth potential. As a growth-oriented pharmaceutical company, Kelon Pharmaceutical needs to find a balance between strengthening traditional businesses and exploring new tracks. On the one hand, it should deepen the domestic market and expand terminal channels. On the other hand, it should prudently plan international markets, introduce high-quality products or pursue technology cooperation to broaden the growth curve. Meanwhile, it can leverage industry resources to explore synergy across the pharmaceutical industry chain and build multiple growth points.

From Gao Chunpo to Wei Zhiguo, Kelon Pharmaceutical’s management reshuffle is a strategic choice for the company to respond to industry transformation and actively seek change. Short-term performance fluctuations do not alter the logic of long-term growth. A solid and resilient fundamental base, a new management team with complementary strengths, and a clear breakthrough direction together form the confidence behind the company’s high-quality development.

As a growth force in the pharmaceutical industry, Kelon Pharmaceutical’s transformation and upgrading reflects China’s pharmaceutical industry’s shift from high-speed growth toward high-quality development. In the wave of centralized procurement becoming normalized and innovation-driven development deepening, enterprises can move steadily only by keeping their main business as the root, using management as the wings, responding to volatility with cyclical thinking, and crossing troughs with a long-term mindset.

This change of leadership is an important milestone in Kelon Pharmaceutical’s development history and also the starting point of a new journey. Under the leadership of Wei Zhiguo and Li Yanbing, the company will address short-term challenges and unlock long-term value with a clearer strategy, more efficient management, and a more resilient operation. It will consolidate its advantages in the fields of specialty chemical drugs and active pharmaceutical ingredients, and move toward the goal of “better products, higher efficiency, and broader boundaries,” continuing the breakthrough and takeoff path of a growth-oriented pharmaceutical company.